Sanofi-Aventis Canada and Intelliject sign license agreement

Sanofi-aventis Canada has announced a licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S and Canada).

"This agreement is in line with sanofi-aventis' diversification strategy. It is also a clear example of actions sanofi-aventis Canada is taking to move away from the traditional model of a pharmaceutical company into a true patient-centric healthcare solutions provider," states Hugh O'Neill, President and CEO sanofi-aventis Canada. "By taking a holistic approach in terms of offering not only products, but services as well as health information, and by redefining the value of such initiatives, we believe that we are setting a new standard of care in Canada".

In Canada, sanofi-aventis will be responsible for leading efforts required to obtain marketing authorization from Health Canada, and thereafter for marketing and selling the product.

Under the terms of the agreement, sanofi-aventis will make an upfront payment and Intelliject will be eligible for future milestone payments and royalties on product sales.

Source: SANOFI-AVENTIS